Adipotide (FTPP): Monkey Studies & Status | Dose Track
App Library Tools Pricing Download
[Peptide · Compound guide]

Adipotide: what it is, animal studies and status

Amounts studied · Approval status · Half-life notes

What is adipotide?

Adipotide (FTPP) is a lab-made peptide designed at MD Anderson Cancer Center to home in on blood vessels that feed white fat and make those vessel cells die, so the fat shrinks. It has been studied in mice and monkeys, has no published human results, and is not approved for human use.

Also known as: FTPP, CKGGRAKDC-GG-D(KLAKLAK)2.

Amounts studied

For adipotide, there is no approved product and no published human results, so there are no label strengths or studied human amounts.

Approval status and how it is used

Adipotide is not approved, and we could not find any published human results.

In the first paper (Kolonin 2004), the researchers found a peptide that sticks to prohibitin on the blood vessels of white fat, and joined it to a peptide that triggers cell death. In obese mice it destroyed white fat and reversed obesity. In obese monkeys (Barnhart 2011), it caused rapid weight loss and better insulin resistance, and at the doses chosen it caused predictable, reversible changes in kidney function (the proximal tubules) in all three monkey species. A published comment (Criscione 2012) argued the monkeys may have lost weight because they ate less, rather than through the fat-vessel effect. Animal results often do not carry over to people.

MD Anderson registered a first-in-human phase 1 trial of a prohibitin-targeting peptide (Prohibitin-TP01) in men with metastatic prostate cancer and obesity. It enrolled 4 people and was terminated at the investigator's request, and no results are posted on ClinicalTrials.gov.

Adipotide half-life and time to peak

  • Half-lifeNot listed
  • Time to peak (Tmax)Not listed

We could not find a published human half-life or time to peak, so we do not list one. Figures quoted online usually come from animal studies.

How to track adipotide in Dose Track

  1. Add adipotide as a custom compound. Start typing its name and Dose Track fills in the details from its research library for you to check, and it sits next to everything else you take.
  2. Log each injection when you give it so your history shows exactly what you took and when.
  3. Set reminders on your own schedule, whether that is daily, weekly or every few days.
  4. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

How Dose Track handles peptides · Reconstitution calculator · Half-life calculator

AOD-9604 5-Amino-1MQ5-amino-1-methylquinolinium, NNMT inhibitor SLU-PP-332

Frequently asked questions

What is the half-life of adipotide?+
We could not find a published human half-life or time to peak, so we do not list one. Figures quoted online usually come from animal studies.
Has adipotide been tested in people?+
No human results have been published. A phase 1 trial of a prohibitin-targeting peptide in men with prostate cancer and obesity (NCT01262664) enrolled 4 people and was terminated, with no posted results. The published research is in mice and monkeys.
Can I track adipotide in Dose Track?+
Yes. Adipotide is in Dose Track's research library, so when you add it as a custom compound its details are filled in for you to check. You can then log each injection next to your other compounds, set reminders on your own schedule, and see your history next to your lab results. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

Sources

  1. Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625-632.
  2. Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112.
  3. Criscione L. Comment on "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys". Sci Transl Med. 2012;4(131):131le2.
  4. ClinicalTrials.gov NCT01262664. A first-in-man, phase I evaluation of a single cycle of prohibitin targeting peptide 1 in patients with metastatic prostate cancer and obesity (M.D. Anderson Cancer Center; terminated).

All compound guides · Reconstitution calculator · Supported medications